Date: Wednesday, March 30, 2016
Location: Medicon Valley Alliance, Copenhagen
Edvard Thomsens Vej 14, Ørestaden
Time: 9:00 am – 4:00 pm (GMT)
Formulation and bioavailability are critical steps in the development process of new effective drugs. One reason for failure in clinical trials might be explained by poor formulation and bioavailability properties of the drug. Meet R&D people, the pharma industry, increase your awareness and gain more knowledge about these topics at this meeting featuring about 100 delgates and 12 exhibitors. The event will be covered by the press.
Catalent Speaking Session
Time: 10:10 am - 10:35 am
Title: Early bioavailability enhancement technology selection
Speaker: Julien Meissonnier, Vice President, Science & Technology, Catalent
During the early stages of the drug development process (i.e. preclinical to Phase I), scientists are often faced with a set of challenges to deliver against the Target Product Profile, with the top three being bioavailability, stability, and delivery profile. A viable bioavailability enhancement toolkit already exists. However, to accelerate development and discharge risk at an early phase, it is essential to examine and rank multiple delivery options in parallel. This approach optimizes the performance of the drug candidates advanced through early preclinical and clinical studies.